Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data from its lead FXR agonist candidate EDP-305 for NASH and PBC. This new data is being presented during The International Liver Congress™ (ILC) 2017, April 19-23, in Amsterdam.

Data from three poster presentations being presented at the Congress will demonstrate that EDP-305 is a potent Farnesoid X Receptor (FXR) agonist that has been shown to reduce expression of fibrogenic genes, reduce fibrosis progression and improve non-alcoholic fatty liver disease (NAFLD) activity scores (NAS) in a variety of preclinical models.

NAFLD is the accumulation of excessive fat in the form of triglycerides in patients' liver cells (steatosis) that is not caused by alcohol. NAFLD is widely considered to be the liver expression of metabolic disease associated with type 2 diabetes, insulin resistance, obesity, and hyperlipidemia. A subgroup of NAFLD patients has liver cell injury and inflammation in addition to excessive fat (steatohepatitis). Progression of this condition leads to non-alcoholic steatohepatitis (NASH). Patients with NASH can develop fibrosis and ultimately cirrhosis of the liver, potentially leading to hepatocellular carcinoma or requiring a liver transplant.

The first poster will be presented by Bryan C. Fuchs, Ph.D., Assistant Professor of Surgery, Harvard Medical School, Massachusetts General Hospital. Poster #THU-377, titled " A Novel Farnesoid X Receptor (FXR) Agonist, EDP-305, Reduces Fibrosis Progression in Animal Models of Fibrosis", demonstrates that EDP-305 reduced fibrosis progression in a choline-deficient, high-fat-diet mouse model of NASH and a rat model of PBC induced by bile duct ligation. Fibrosis progression was measured by quantitative molecular imaging of collagen crosslinking and Type 1 collagen, markers that are sensitive to changes in fibrosis.

The second poster will be presented by Lijuan Jiang, Ph.D., Executive Director DMPK and Bioanalysis, Enanta Pharmaceuticals, Inc. Poster #FRI-363, titled " EDP-305, a Novel and Highly Potent Farnesoid X Receptor (FXR) Agonist, Improves Liver Steatosis, Ballooning and Non-Alcoholic Fatty Liver Disease (NAFLD) Activity Score (NAS) in a Diet-Induced Murine Model of Non-Alcoholic Steatohepatitis", demonstrates that EDP-305 exerts beneficial pharmacological effects in a dietary-induced NASH (DIN) mouse model that mimics the human NAFLD/NASH physiological setting. In addition to reducing plasma and liver lipid content, EDP-305 showed a significant decrease in hepatocyte ballooning, and NAS in DIN mice, suggesting that EDP-305 may have potential beneficial effects in treating NASH.

The third poster will be presented by Yury Popov, M.D., Ph.D., Staff Scientist, Beth Israel Deaconess Medical Center and Assistant Professor of Medicine, Harvard Medical School. Poster #SAT-459, titled " A Novel FXR Agonist EDP-305 Potently Suppresses Liver Injury and Fibrosis in Mouse Models of Biliary and Metabolic Liver Disease", demonstrates that treatment with EDP-305 potently improved pre-established liver injury and hepatic fibrosis in biliary (BALBc.Mdr2-/-) and metabolic (MCD) models of liver disease in mice.

"The BALBc.Mdr2-/- mouse model may represent the most relevant model that we have to evaluate the potential of new agents for the treatment of primary sclerosing cholangitis (PSC). We are very encouraged by the results we have observed with EDP-305 showing a very robust response in this biliary disease model," stated Yury Popov, M.D., Ph.D.

If you liked this article you might like

Strong On High Relative Volume: Enanta Pharmaceuticals (ENTA)

Insider Trading Alert - ENTA, EBIO And PSEC Traded By Insiders

5 Hated Stocks You Should Love

Insider Trading Alert - ENTA, HBI And MOFG Traded By Insiders

Enanta Pharmaceuticals (ENTA) Showing Signs Of Perilous Reversal Today